SCHOFIELD, Wis., Aug. 5, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCPink: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it plans to begin testing of a new hemp-based epilepsy medication in the fourth quarter of 2014.
"As we looked at the similarities between migraine and epilepsy the treatment path became obvious," said Russell Mitchell, CEO and Chairman of PuraMed BioScience. "Epilepsy and migraine seem to be triggered by the same coritcal spreading depression (CSD) in the brain; the difference is the rate of reaction. This may be why many migraineurs are prescribed epileptic medications."
According to an article in Seizure, the prevalence of migraine in people who experience epilepsy is 8.4 to 20 percent. In addition to migraine, an estimated 64 percent of epilepsy sufferers also experience seizure-related (ictal) headaches: 20 percent experience headache prior to the seizure (pre-ictal) and 44 percent experience headache after the seizure (post-ictal).
The third most common neurological disorder in the US, epilepsy affects approximately 2.7 million people, with children and older adults being most susceptible. The condition also causes up to 50,000 sudden deaths each year.
Epilepsy affects veterans wounded in combat. According to Citizens United to Cure Epilepsy, approximately 22 percent of the 440,000 military service men and women who experienced traumatic brain injury are expected to develop post-traumatic epilepsy.
"An epilepsy medication is a natural extension to our product line," said Mitchell. "We have developed a formula, now we will begin the setting up the trials. We have been approached by key researchers who have expressed interest in working with us on CBD-based products.
"Standardization is key to creating a quality sublingual formula," said Mitchell. " Sublingual delivery offers the distinct advantages of faster delivery and efficiency while avoiding the "first pass effect" that often degrades oral medications. Our goal is to build medicines that withstand scientific scrutiny and perform well in double-blind, placebo controlled clinical trials. We believe that the efficacy of our formulations will be proven by scientific trials. This type of testing lends credibility to our line of natural medications which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts."
Currently, PuraMed BioScience is rebranding its flagship product, LipiGesic M, as MigraPure.
MigraPure uses the same sublingual feverfew and ginger formula that was clinically tested as LipiGesic M. The flavor of this homeopathic, all-natural, over-the-counter migraine headache pain relief medication has been enhanced, but the active ingredients that stop disabling migraine pain and associated symptoms quickly, is the same. MigraPure's feverfew and ginger gel is non-drowsy and non-habit forming. MigraPure is not associated with rebound headaches. MigraPure has an excellent safety profile and has no reported drug interactions.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to rebranding LipiGesic M to MigraPure, PuraMed BioScience plans to launch additional cannabinoid-enhanced, anti-inflammatory, and anxiolytic products as it moves forward in the development of its cannabinoid product line.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
|SOURCE PuraMed BioScience, Inc.|
Copyright©2014 PR Newswire.
All rights reserved